{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T12:04:42Z","timestamp":1789992282277,"version":"4.0.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1067\/mob.2001.116371","type":"journal-article","created":{"date-parts":[[2002,8,24]],"date-time":"2002-08-24T22:14:26Z","timestamp":1030227266000},"page":"56-61","source":"Crossref","is-referenced-by-count":69,"title":["Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis"],"prefix":"10.1067","volume":"185","author":[{"given":"Marie-Andr\u00e9e","family":"Harvey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George A.","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1067\/mob.2001.116371_bib1","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/nau.1930070502","article-title":"Standardization of terminology of lower urinary tract function","volume":"7","author":"Abrams","year":"1988","journal-title":"Neurourol Urodyn"},{"key":"10.1067\/mob.2001.116371_bib2","article-title":"Epidemiology and natural history of urinary incontinence (UI)","author":"Hunskaar","year":"1999"},{"key":"10.1067\/mob.2001.116371_bib3","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0024-3205(97)00057-X","article-title":"Tolterodine: a new bladder selective, muscarinic receptor antagonist: preclinical pharmacological and clinical data","volume":"60","author":"Nilivelbrant","year":"1997","journal-title":"Life Sci"},{"key":"10.1067\/mob.2001.116371_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1067\/mob.2001.116371_bib5","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials","volume":"273","author":"Schulz","year":"1995","journal-title":"JAMA"},{"key":"10.1067\/mob.2001.116371_bib6","first-page":"276","article-title":"A randomized, double blind placebo controlled, dose ranging study of the safety and efficacy of tolterodine in patients with hyperreflexia","author":"Abrams","year":"1996"},{"key":"10.1067\/mob.2001.116371_bib7","first-page":"67","article-title":"Tolterodine for overactive bladder: time of onset of action, preferred dosage and 9-month follow up","volume":"5","author":"Atan","year":"1999","journal-title":"Tech Urol"},{"issue":"suppl 2","key":"10.1067\/mob.2001.116371_bib8","first-page":"S26","article-title":"Tolterodine: a well tolerated, safe and effective long-term treatment for patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1067\/mob.2001.116371_bib9","first-page":"S30","article-title":"Tolterodine reduces the number of incontinence episodes in patients with detrusor overactivity","volume":"8","author":"Jacquetin","year":"1997","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1067\/mob.2001.116371_bib10","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1471-0528.1997.tb12054.x","article-title":"A medium term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance","volume":"104","author":"Kelleher","year":"1997","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1067\/mob.2001.116371_bib11","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0090-4295(98)00629-3","article-title":"Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data","volume":"53","author":"Larsson","year":"1999","journal-title":"Urology"},{"key":"10.1067\/mob.2001.116371_bib12","first-page":"343","article-title":"Clinical and urodynamic efficacy of tolterodine: a multicentre placebo-controlled study","volume":"16","author":"Millard","year":"1997","journal-title":"Neurourol Urodyn"},{"key":"10.1067\/mob.2001.116371_bib13","first-page":"S129","article-title":"A randomized controlled multicentre trial of tolterodine in detrusor instability hyperreflexia","volume":"8","author":"Moore","year":"1997","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1067\/mob.2001.116371_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1046\/j.1464-410x.1998.00501.x","article-title":"Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study","volume":"81","author":"Rentzhog","year":"1998","journal-title":"Br J Urol"},{"key":"10.1067\/mob.2001.116371_bib15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/nau.1930140606","article-title":"Urodynamic and other effects of tolterodine: a novel antimuscarinic drug for the treatment of detrusor overactivity abstract","volume":"14","author":"Stahl","year":"1995","journal-title":"Neurourol Urodyn"},{"key":"10.1067\/mob.2001.116371_bib16","first-page":"117","article-title":"Age comparisons of the safety and efficacy of tolterodine form twelve weeks studies","volume":"17","author":"Malone-Lee","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"10.1067\/mob.2001.116371_bib17","first-page":"217","article-title":"Everyday life safety and road safety after treatment with drugs against incontinence: recent studies of the safety potential of urologic anticholinergics","volume":"50","author":"Hergerg","year":"1999","journal-title":"Die Medizinische Welt"},{"key":"10.1067\/mob.2001.116371_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/(SICI)1520-6777(1998)17:6<599::AID-NAU4>3.0.CO;2-J","article-title":"Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model","volume":"17","author":"Kobelt","year":"1998","journal-title":"Neurourol Urodyn"},{"key":"10.1067\/mob.2001.116371_bib19","first-page":"177","article-title":"A comparative study of tolterodine and oxybutynin for the treatment of urine incontinence","volume":"10","year":"1998","journal-title":"Ther Erfolg Urol Nephrol"},{"key":"10.1067\/mob.2001.116371_bib20","first-page":"S14","article-title":"Enhanced tolerability of tolterodine compared to oxybutynin in a controlled clinical study","volume":"8","author":"Drutz","year":"1997","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"issue":"suppl 167","key":"10.1067\/mob.2001.116371_bib21","first-page":"24","article-title":"Clinical efficacy and safety of tolterodine vs oxybutynin and placebo in patients with unstable bladder","volume":"76","author":"Drutz","year":"1997","journal-title":"Acta Obstet Gynecol Scand"},{"key":"10.1067\/mob.2001.116371_bib22","first-page":"240","article-title":"Tolterodine in the treatment of urge incontinence. Analysis of the pooled phase II efficacy and safety data","author":"Larsson","year":"1996","journal-title":"Neurourol Urodyn"},{"issue":"suppl 6A","key":"10.1067\/mob.2001.116371_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0090-4295(97)00599-2","article-title":"Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis","volume":"50","author":"Appell","year":"1997","journal-title":"Urology"},{"key":"10.1067\/mob.2001.116371_bib24","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1046\/j.1464-410x.1999.00004.x","article-title":"Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine","volume":"83","author":"Kobelt","year":"1999","journal-title":"BJU Int"},{"issue":"suppl 2","key":"10.1067\/mob.2001.116371_bib25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1046\/j.1464-410X.83.s2.10.x","article-title":"Treatment of the overactive bladder with tolterodine, a new muscarinic receptor antagonist","volume":"83","author":"Messelink","year":"1999","journal-title":"BJU Int"},{"key":"10.1067\/mob.2001.116371_bib26","first-page":"163","article-title":"The comparative tolerability and efficacy of tolterodine 2 mg bid versus oxybutynin 2.5\/5 mg bid in the treatment of the overactive bladder","volume":"17","author":"Malone-Lee","year":"1998","journal-title":"Neurourol Urodyn"},{"issue":"suppl 1","key":"10.1067\/mob.2001.116371_bib27","first-page":"S78","article-title":"Treatment with tolterodine significantly improves social function and energy in patients with overactive bladder","volume":"10","author":"Malone-Lee","year":"1999","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1067\/mob.2001.116371_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1046\/j.1464-410x.1998.00717.x","article-title":"Tolterodine, a new cholinergic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder","volume":"81","author":"Abrams","year":"1998","journal-title":"Br J Urol"},{"key":"10.1067\/mob.2001.116371_bib29","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s001929970003","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder","volume":"10","author":"Drutz","year":"1999","journal-title":"Int Urogynecol J Pelvic Floor Dysfunct"},{"key":"10.1067\/mob.2001.116371_bib30","first-page":"478","article-title":"Clinical efficacy and safety of tolterodine compared to oxybutynin in patients with overactive bladder","volume":"16","author":"Van Kerrebroeck","year":"1997","journal-title":"Neurourol Urodyn"},{"issue":"5","key":"10.1067\/mob.2001.116371_bib31","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0022-5347(05)66326-4","article-title":"Tolterodine: superior tolerability and comparable efficacy to oxybutynin in individuals 50 years or older with overactive bladder: a randomized controlled trial","volume":"165","author":"Malone-Lee","year":"2001","journal-title":"J Urol"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937801270987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937801270987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T00:01:07Z","timestamp":1703894467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937801270987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["S0002937801270987"],"URL":"https:\/\/doi.org\/10.1067\/mob.2001.116371","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}